Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J&J’s Symtuza Approved, But Commercial Outlook Uncertain

Jul 18 2018

• By Joseph Haas

HIV-AIDS pills_1200x675

Related Content

J&J's Symtuza Will Debut In Europe On Cramped HIV Market

Jul 24 2017

HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End

Apr 18 2018

Janssen's Darunavir-Based Single-Tablet Effective In Late-Stage Switching Study

Oct 09 2017

AMBER Data Support Green Light For Janssen's Symtuza

Oct 26 2017

How Will Novel Agents Impact The HIV Market?

Apr 17 2018

Related Companies

Johnson & Johnson

Gilead Sciences, Inc.

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

ViiV Healthcare

Bristol Myers Squibb Company

Additional Topics

Approvals Commercial Business Strategies Infectious Diseases BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window